Mission:
To promote excellence in clinical care through research and education.
 
 
  Learn More...



Current Staff
 
Director:  John W. Goethe, M.D.
Jessica Bello, M.O.L.
Sherri Post, B.A.
Charles Caley, Pharm.D. (UConn)
Bonnie Szarek, R.N.
Alex Cardoni, M.S. Pharm.
Cailyn Welsh, B.S.
Julia Golden, B.A.
Andrew Winokur, M.D., Ph.D.
Jessica Howard, B.A.
Stephen Woolley, D.Sc., M.P.H.
Katherine Keating, M.A. Brenda Woznicki, B.A.

(top)
 

 
Clinical Information Management
The Burlingame Center supports quality management and program evaluation activities, monitors clinical care (e.g., evidence-based practices), maintains practice guideline documents, and conducts research related to hospital operations.

 

The Clinical Evaluation and Monitoring System (CEMS)
The Burlingame Center operates the hospital's computerized clinical decision support system CEMS.  This automated decision support system, developed by John W. Goethe, M.D. and Bonnie L. Szarek, R.N., supports the goal of assuring the optimal outcome for every patient. The components of the system are:

  • Psychotropic Guidelines: This on-line document summarizes key information about the use of selected psychiatric medications (dosages, therapeutic serum levels, indications and side effects). It also presents "decision trees" to guide drug selection. (more)
  • Information Alerts: These computer-generated messages notify clinicians of events that do not conform to practice guidelines and medication protocols. Clinicians may respond to these notices by changing the treatment plan/diagnosis/laboratory orders to comply with "usual practice" (defined in the Pharmacotherapy Guidelines) or by documenting the reason for alternative treatment, using a standard form to record the response. (The response is then automatically entered as a progress note in the patient’s medical record.)
  • Diagnostic Checklists (DCLs): The DCLs provide an automated method for assuring documentation of the key symptoms and behavioral issues that support the assigned diagnosis and for noting the degree of change in each symptom/behavior at subsequent evaluations (e.g., at discharge). There is a separate checklist for each psychiatric diagnosis that reflects DSM criteria for that diagnosis.
  • Outcome Assessment Program (OAP): Clinical staff interview every patient at admission and discharge, using a brief questionnaire to assess items related to functioning and productivity. The patient is contacted at one, six, and twelve months post-discharge to assess functional status and subsequent psychiatric treatment received.  Manager: Steve Woolley, M.P.H., D.Sc. Coordinator: Brenda Woznicki.
Investigational Therapies Service
This service, directed by Drs. John Goethe and Andrew Winokur, offers access to psychiatric medications that are currently in development but not yet approved for use in routine clinical care. These medications can only be administered to individuals who participate in a formal research study. Click here for information about current studies.

Mood Disorders Consultation Service
The Mood Disorders Consultation Service at The Institute of Living is designed to help people whose mood disorders have so far been resistant to therapy. The behavioral health community increasingly recognizes that recovery—not just response—must be the ultimate goal of therapy. Full recovery is the overarching goal of our program. We continue to work with each patient until we have identified the optimal treatment and outcome. (more)

(top

 

 
Professional Education Activities Include:

Grand Rounds:
Weekly educational conferences covering a variety of topics related to mental health and psychiatric practice.  Grand Rounds are accredited for continuing medical education and are presented Thursday afternoons 12:00 PM - 1:15 PM, September through June. (more)
 
Psychopharmacology and Neuroscience Rounds:
This series focuses on applied psychopharmacology and research on brain structure and function.  Held once monthly from September through June on Wednesday at 12:00 noon in the Hartford Room, Commons Building, The Institute of Living. (more)
 
(top)
 

 
Current Research Studies (selected list):
  • A 104-Week, Flexible-dose, Open-label, Multi-center, Extension Study to Evaluate the Long-term Safety and Effectiveness of Lurasidone in Pediatric Subjects with Schizophrenia and Subjects with Irritability Associated with Autistic Disorder (D1050302) - Salma Malik, M.D., M.S., Principal Investigator
  • An Adaptive, Phase IIB/III, Double-blind, Randomized, Placebo-controlled, Multi-center Study of the Safety and Efficacy of Naben® (Sodium Benzoate), a Damino Acid Oxidase Inhibitor, as an Add-On Treatment for Schizophrenia in Adolescents (SNR-01-NaBen)- John W. Goethe, M.D., Principal Investigator
  • Assessment of a Suicide Screening Program to Improve Detection of Post-discharge Suicide Risk - Stephen Woolley, M.P.H., D.Sc., Principal Investigator
  • A Multi-center, Double-blind, Placebo- and Active-Controlled Parallel-group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients with Major Depressive Disorder (VLZ_MD_22) - Salma Malik, M.D., M.S., Principal Investigator
  • An On-going Collaboration with the Mental Health in Independent School Communities Program (Rosemary Baggish, M.Ed., M.P.H. Director and Peter Wells, Ph.D., Senior Consultant) – John W. Goethe, M.D. and Stephen B. Woolley, D.Sc., Research Consultants
  • An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients with Major Depressive Disorder (VLZ_MD_23) - Salma Malik, M.D., M.S., Principal Investigator
  • A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Social Anxiety Disorder (42165279SAX2001) - Andrew Winokur, M.D., Ph.D., Principal Investigator
  • A Phase III, Multi-center, 4-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Current or Most Recent Episode Manic) - Salma Malik, M.D., M.S., Principal Investigator
  • A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder who Have Responded to Antidepressant Treatment (OBSERVEMDD0001) - Andrew Winokur, M.D., Ph.D., Principal Investigator
  • A Randomized, 6-Week, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects with Bipolar I Depression (D1050326) - Salma Malik, M.D., M.S., Principal Investigator
  • A Randomized, Double-blind, Multi-center, Active-controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression (ESKETINTRD3003) - Andrew Winokur, M.D., Ph.D., Principal Investigator
  • Risk of Metabolic Syndrome Among Psychiatric Patients with Depressive Disorders Treated with Second-Generation Antipsychotics: Roles of Stress and Inflammation - Stephen Woolley, M.P.H., D.Sc., Principal Investigator
  • SPRITES: Sertraline Pediatric Registry for the Evaluation of Safety - A Non-interventional, Longitudinal, Cohort Study to Evaluate the Effects of Long-term Sertraline Treatment in Children and Adolescents - Scott Hannan, Ph.D., Principal Investigator; Salma Malik, M.D., M.S., Sub-Investigator
  • The Utility of Routine Cytochrome P450 Genotyping in the Selection of Type and Dosage of Antidepressant Medication - John W. Goethe, M.D., Principal Investigator   
(top)
 

 
Selected Publications and Presentations (Jan 2010-Dec 2015):
  • Baggish R, Wells PH, Goethe JW, Woolley SB.  Suicide Attempts in Private School Adolescents.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Baggish R, Wells P, Goethe JW, Woolley SB.  Setting the Stage: Suicide Indicators of Risk and Protection Among Private School Students.  Presented at Psychiatric Grand Rounds, The Institute of Living, Hartford, CT, September 10, 2013.
  • Blair EW, Woolley SB, Szarek BL, Mucha TF, Dutka O, Schwartz HI, Goethe JW, Wisniowski J.  Action Research: Testing Interventions to Prevent Violence in Inpatient Psychiatric Settings.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Blair EW, Woolley SB, Szarek BL, Mucha TF, Dutka O, Schwartz HI, Goethe JW, Wisniowski J.  Evidence of the Success of Interventions to Prevent Violence and Reduce Use of Seclusion and Restraint in an Inpatient Psychiatric Setting.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Blair EW, Szarek BL, Woolley SB, Mucha TF, Dutka O, Schwartz HI, Goethe JW.  Variables associated with falls among psychiatric inpatients: The Institute of Living Falls Intervention Initiative.   Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Blair EW, Szarek BL, Azhar N.  Survey of osteoporosis in an inpatient geriatric psychiatric setting: a pilot study.  Issues in Mental Health Nursing, 31(6):403-407, 2010.
  • Blank K, Szarek BL, Goethe JW.  Metabolic abnormalities in adult and geriatric major depression with and without co-morbid dementia.  The Journal of Clinical Hypertension, 12(6):456-461, 2010.
  • Bonetti J, Szarek BL, Goethe JW.  Current prescribing practices: antipsychotic polypharmacy in patients with schizophrenia and schizoaffective disorder.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Bullock K, Szarek BL, Goethe JW.  Racial differences in major depressive disorder presentation.  Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.
  • Caley CF. Depression in the Elderly: Opportunities for the Community Pharmacist.  Presented to licensed pharmacist attendees at the Crowne Plaza Hotel, Cromwell, CT, October 2015.
  • Caley CF, Malik S.  How The Science of Pharmacogenetics Influences the Art of Individualized Patient Care.  Presented to attendees of the Joint Meeting of the American Society for Adolescent Psychiatry and the International Society for Adolescent Psychiatry and Psychology, New York, NY, March 2015.
  • Caley CF.  Schizophrenia.  Medication Therapy Management: A Pharmacotherapy and Medication System Primer. Whalen K ed, McGraw Hill, New York, NY: available from AccessPharmacy, October 2014. (online book chapter)
  • Caley CF.  Report on medication use for medicaid use for children diagnosed with ADHD.  Prepared for the State of Connecticut Children’s Mental Health Task Force. Presented to Task Force, July 2014.
  • Caley CF.  Developing a first-line obsessive-compulsive disorder treatment plan: a case of newly diagnosed OCD.  In: Grady SE, McGuire JM, Nelson JA, Rappa L, editors. Psychiatric Pharmacotherapy Case Series. Lincoln (NE): College of Psychiatric and Neurologic Pharmacists, 11p, 2014.
  • Caley CF.  Developing an obsessive-compulsive disorder (OCD) treatment plan: a case of first-line OCD treatment failure.  In: Grady SE, McGuire JM, Nelson JA, Rappa L, editors. Psychiatric Pharmacotherapy Case Series. Lincoln (NE): College of Psychiatric and Neurologic Pharmacists, 12p, 2014.
  • Caley CF.  Developing an obsessive-compulsive disorder treatment plan: a case of treatment-resistant obsessive-compulsive disorder.  In: Grady SE, McGuire JM, Nelson JA, Rappa L, editors. Psychiatric Pharmacotherapy Case Series. Lincoln (NE): College of Psychiatric and Neurologic Pharmacists, 12p, 2014.
  • Caley CF. Getting Started with Patient Care and Practice Transformation.  Presented to attendees of a national webinar sponsored by the College of Psychiatric and Neurologic Pharmacists, Lincoln, NE, November 2013.
  • Caley CF. Optimizing Treatment of Psychosis and Neuropsychotic Disorders in the Elderly: The Pharmacist’s Role.  Presented to attendees of the annual New England Pharmacists Convention, MGM Foxwoods Casino, Ledyard, CT, September 2013.
  • Caley CF. Psychotropics in the Pipeline.  Presented to medical and professional staff for Grand Rounds, Riverview Hospital, Middletown, CT, September 2013.
  • Caley CF. Genotyping the Patient Requiring Mental Health Medications: When Does It Make Sense?  Presented to attendees of the annual American College Health Association Meeting, Copley Place Marriott, Boston, MA, May 2013.
  • Caley CF. Supporting Individuals with Mental Health Conditions: What More Can We Do?  Presented to attendees of the 36th Annual Schwarting Symposium, University of Connecticut, Storrs, CT, May 2013.
  • Caley CF. Behavioral and Psychological Symptoms in Dementia: Beyond the Antipsychotics.  Presented to Senior Symposium attendees, Foxwoods Grand Pequot Hotel, Ledyard, CT, March 2013.
  • Caley CF. Potential interactions between psychoactive medications and other prescriptions.  Presented to attendees of the Attention Deficit/Hyperactivity Disorder Conference & Symposium, University of Alabama, Tuscaloosa, AL, January 2013.
  • Caley CF. Understanding the neuropharmacology of ADHD.  Presented to attendees of the Attention Deficit/Hyperactivity Disorder Conference & Symposium, University of Alabama, Tuscaloosa, AL, January 2013.
  • Caley CF, Stimmel GL.  Characterizing the relationship between individuals with mental health conditions and community pharmacists.  CPNP Foundation Report, December 2012.
  • Caley CF.  Psychopharmacology for the elderly: focus on depression, psychosis, and bipolar disorder.  Drug Topics, 15(6):30–8, 2012.
  • Caley CF, Thomas M.  Blueprint for change: building a better ADHD treatment regimen for college students.  Presented at the Annual Meeting of the American College Health Association, Chicago, IL, May 2012.
  • Caley CF.  Evaluating Poor Treatment Outcomes: Clinical Pharmacokinetic Considerations.  Presented to medical staff for Grand Rounds, Riverview Hospital, Middletown, CT, January 2012.
  • Caley CF.  Antidepressants: Addressing Key Safety Issues.  Presented to pharmacists at the annual December CE event sponsored by the Connecticut Pharmacists Association, Marriott Hotel, Rocky Hill, CT, December 2011.
  • Caley CF.  Applying Medication Therapy Management to Mental Health.  Presented to attendees at the annual New England Pharmacists Convention, MGM Foxwoods Casino, Ledyard, CT, September 2011.
  • Caley CF.  Influence of CYP2 Genotyping on Psychiatric Pharmacist Consultations.  Presented to attendees at the Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Phoenix, AZ, May 2011.
  • Caley CF.  Interpreting and applying CYP450 genomic test results to psychotropic medications.  J Pharm Pract, 24(5):439–6, 2011.
  • Cardoni AA.  Opiod Dependence: From Cold Turkey to Acute Detox.  Psychopharmacology/Neuroscience Rounds, Institute of Living, Hartford, CT, February 16, 2011.
  • Cardoni AA.  Opiod Dependence: Clinical Pharmacology and Treatment.  Presented at the Henry A. Palmer C.E. Finale 2010, Storrs, CT, December 17, 2010.
  • Cardoni AA.  Management of Treatment-Resistant Depression - An Update.  Presented at the 33rd Annual Arthur E. Schwarting Pharmacy Practice Symposium, Storrs, CT, May 27, 2010.
  • Diefenbach GJ, Assaf M, Bragdon LB, Goethe JW, Hyatt C, Tolin D.  A Randomized, Double-Blind, Sham-Controlled Clinical Trial of rTMS for Generalized Anxiety Disorder.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Diefenbach GJ, Bragdon L, Goethe JW.  Treating anxious depression using repetitive transcranial magnetic stimulation.  J Affect Dis, 151:365–8, 2013.
  • Diefenbach GJ, Goethe JW.  Effectiveness of transcranial magnetic stimulation (TMS) for anxious depression.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Ehret M, Szarek BL, Goethe JW.  Is antidepressant use in bipolar disorder associated with readmission?  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Ehret MJ, Szarek BL, Goethe JW.  Current prescribing practices: antidepressant use in schizophrenia. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Goethe JW, Szarek BL, Woolley SB.  Are Antidepressants Associated with Increased Risk of Poor Outcome in Bipolar Patients? Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2015.
  • Goethe JW, Wisniowski J, Szarek BL, Woolley SB.  Metabolic Syndrome Associated with Severity of Illness and Outcomes among Inpatients with Mood Disorders.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Goethe JW.  Psychoanalytic theory informs “biological” psychiatry.  Presented at the Annual Meeting of the World Psychiatric Association, Vienna, Austria, October 2013.
  • Goethe JW, Szarek BL, Chmielecki L, Ruaño G, Seip R.  The case for routine genotyping in the management of patients with MDD.  Presented at the Annual Meeting of the World Psychiatric Association, Vienna, Austria, October 2013.
  • Goethe JW, Szarek BL, Woolley SB.  Changes in pharmacotherapy in severe major depressive disorder:  a 12-month study of physician and patient treatment decisions.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Goethe JW, Szarek BL, Woolley SB.  Is posttraumatic stress disorder associated with increased risk of metabolic syndrome among inpatients with mood disorders?  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Goethe JW, Szarek BL.  Diagnostic stability in major depressive disorder with versus without psychotic features.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Goethe JW, Szarek BL.  Inpatients with psychotic vs. nonpsychotic MDD: prevalence and clinical characteristics. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.  
  • Hawthorne J, Caley CF.  Extrapyramidal reactions associated with serotonergic antidepressants: a follow-up literature review.  Annals of Pharmacotherapy, 2015.
  • Malik S, Caley CF, Azeem MW.  Psychopharmacogenomics – a new tool for the prescribing physician.  Journal of Pakistan Psychiatric Society, 11(2):12–15, 2014.
  • Padole A, Woolley SB, Szarek BL, Goethe JW.  Variables Associated with 3-Month Incidence of Readmission: Patients with Schizophrenia versus Schizoaffective Disorder. Poster presentation at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Perriello E, Caley CF.  Literature review of studies investigating anticonvulsants and suicidal behavior in bipolar disorder (poster). Annual meeting of the College of Psychiatric and Neurologic Pharmacists, Phoenix, AZ, April 2014.
  • Ruaño G, Seip RL, Goethe JW, Thompson S, Tortora J, Campbell S, Szarek BL, Schwartz HI.  CYP GUIDES: A Randomized Controlled Trial to Evaluate Pharmacogenetic Decision Support in Inpatients with Depression. Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2015.
  • Ruaño G, Seip RL, Szarek BL, Schwartz HI, Goethe JW.  Rate of Patient Readmission Following Psychiatric Hospitalization for Major Depressive Disorder Correlated with Innate CYP2D6 Function.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Ruaño G, Szarek BL, Villagra D, Gorowski K, Kocherla M, Seip RL, Goethe JW, Schwartz HI.  Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomarkers in Medicine, 7(3): 429-439, 2013.
  • Ruaño G, Seip RL, Gorowski K, Szarek B, Schwartz HS, Goethe JW.  Changes in psychotropic prescription during hospitalization of depressed patients correlated with innate CYP2D6 function. Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Ruaño G, Gorowski K, Szarek BL, Seip R, Kocherla M, Goethe JW.   High prevalence and significant pharmacokinetic implications of the CYP2C19 ultra-rapid allele *17 allele in psychotropic-treated patients.  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Ruaño G, Villagra D, Szarek B, Windemuth A, Kocherla M, Gorowski K, Berrezueta C, Schwartz HI, Goethe JW.  Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients.  Biomarkers in Medicine, 5(4):439-449, 2011.
  • Ruaño G, Villagra D, Szarek BL, Windemuth A, Kocheria M, Berrezueta CD, Goethe JW.  Dyslipidemia in psychotropic-treated patients correlates with combinatorial CYP405 drug metabolism indices. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Ruaño G, Villagra D, Szarek BL, Windemuth A, Kocheria M, Goethe JW: Longer hospitalization associated with combinatorial CYP450 drug metabolism deficiencies. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010
  • Schwartz HI, Goethe JW, Szarek BL, Woolley SB.  Data available on admission predict 30-day readmission in psychiatric inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Schwartz HI, Woolley SB, Goethe JW, Szarek BL.   Inpatient psychiatric care: consequences of short LOS.  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Stevens MC, Szarek BL, Goethe JW.  Current prescribing practices: antipsychotic use in children and adolescents.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Szarek BL, Goethe JW, Woolley SB.  Course of illness over 12 months in patients with major depressive disorder.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Szarek BL, Goethe JW, Chmielecki L.  Diagnostic stability in patients with DSM-IV diagnosis of bipolar disorder.  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Szarek BL, Goethe JW.  Patterns of antipsychotic use in hospitalized psychiatric patients.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Szarek BL, Goethe JW.  Metabolic syndrome in psychiatric inpatients: The role of valproate and lithium.  Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.
  • Villagra D, Goethe JW, Schwartz HI, Szarek B, Kocherla M, Gorowski K, Windemuth A, Ruaño G.  Novel drug metabolism indices for pharmacogenetic functional status based on combinatorial genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.  Biomarkers in Medicine, 5(4):427-438, 2011.
  • Windemuth A, de Leon J, Goethe JW, Schwartz HI, Woolley SB, Susce M, Kocherla M, Bogaard K, Holford TR, Seip RL, Ruaño G.  Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.  Progress in Neuro-Psychopharmacology and Biological Psychiatry, 36(2):213-219, 2012.
  • Wisniowski J, Woolley SB, Goethe JW, Klein L, Szarek BL, Pizzuto B.  Characteristics of Adult Psychiatric Patients Readmitted Within 30 Days After Psychiatric Hospitalization.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Woolley SB, Goethe JW, Szarek BL, Wells PH, Baggish RC.  Disordered Sleep and Stress among Private High School Students: Independent and Combined Effects on Suicide Risk. Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2015.
  • Woolley SB, Terrell K, Goethe JW.  Psychiatric Patients’ Self-Assessment of Body Weight is Associated with Risk of Metabolic Syndrome.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Woolley SB, Goethe JW.  Risk factors for post discharge suicidality among child and adolescent psychiatric inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Woolley SB, Goethe JW, Cohn RL.  Insomnia, anxiety, and suicidal ideation.  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Woolley SB, Goethe JW, Szarek BL.  Risks of Readmission in Patients Diagnosed with Bipolar, Major Depressive, or Schizoaffective Disorders: a Longitudinal Study. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Woolley SB, Cardoni AA, Goethe JW.  An additional source of bias in antidepressant and other trials (authors' reply).  Pharmacotherapy, 30:117e-8e, 2010.
  • Woolley SB, Goethe JW, Szarek BL, Tronsky M. The Association between pre-admission suicidality and readmission was modified by patient experiences, feelings and characteristics. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.  
  • Wootton B, Bragdon LB, Diefenbach GJ, Goethe JW, Tolin D.  Transcranial Magnetic Stimulation for Depression also Improves Anxiety Symptoms: A Meta-Analysis of Randomized-Controlled Trials.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
(top